Data indicate 2 out of 5 patients utilized LVR services among those who received a referral recommendation during the CDSS active phase, while onsite LVR service provision increased utilization rates.

We all want to provide quality care for our patients, but how can you be sure that you are providing it? There are a number of indicators associated with quality care in rheumatoid arthritis. Take this quiz to see how many you can identify.

Kim Zuber, PA-C, and Jane Davis, DNP, provide perspective on guideline recommendations for the management of hepatitis C in people with chronic kidney disease from the Kidney Disease Improving Global Outcomes.

New research into the use of ustekinumab compared to other treatments for psoriasis sheds light on risk for outpatient infections.

Peter A. Lio, MD, shares his approach to presenting treatment alternatives to patients who want to stop using long-term steroids for treatment of AD.

Adelaide A. Hebert, MD, comments on the need for nondermatologist education on the basics of skin disease care.

Drs Diana Isaacs and Natalie Bellini highlight the need for engaging patients in shared decision-making and addressing social determinants of health in diabetes and obesity management in adults and pediatric patients.

Scott Kahan, MD, MPH, discusses with Diana Isaacs and Natalie Bellini how the controversial use of new diabetes and obesity medications is creating access issues for people who really need these medications, and shares strategies to initiate the conversation about weight management with patients.

Dr Scott Kahan shares the latest updates to the 2023 ADA Standards of Care related to weight management and describes the different weight loss approaches recommended by the ADA.

Scott Kahan, MD, MPH, discusses the shortcomings of the current staging systems used for overweight and obesity and recommends the use of weight-related health and functional status in addition to BMI.

The connection between different ADHD subtypes and mood disorders has not been fully explored.

Further adding to the discussion surrounding the impact of endocrine-disrupting chemicals, an analysis of data from the SWAN Multipollutant Study suggests increased exposure to phthlates was linked to a 30-63% increase in risk of developing diabetes among White women in midlife.

New research into the nursing home CMS rating system suggests that a revision may improve the public’s information access.

Latino-English preferred patients had an overall lower rate of screening compared to both non-Hispanic whites and Latino-Spanish preferred patients.

Results may help minimize the risk of developing hyperuricemia, gout, and related adverse events in patients receiving antihypertensive drugs.

The positivity rate of rhinoviruses and enteroviruses decreased briefly following the onset of the COVID-19 pandemic, but by fall of 2020 resumed almost to pre-pandemic levels.

New 6-month findings from a First-in-Human glaucoma treatment trial indicate the drug delivery platform continued to show a 45% reduction in mean intraocular pressure.

As an industry and a society, we must take gout more seriously. That effort begins with the physicians who diagnose and treat it.

Aflibercept treatment resulted in statistically significant anatomic improvement, but no improvement in visual acuity among patients with NPDR without CI-DME at 4 years of analysis.

The results also show a decrease in antibiotic use, hospital length of stay, and overall cost to the patient.

New research was found on alcohol consumption as a modifiable risk factor in dementia, in a study out of South Korea.

The treatment is a novel, investigational anti-C5 recycling monoclonal antibody showing promise for treating patients with paroxysmal nocturnal hemoglobinuria.

Leveraging data from the Tromsø study, the D2d study, and the DPVD study, a systematic review and meta-analysis concluded vitamin D supplementation could help reduce risk of progression to diabetes by 15% among people with prediabetes.

Thus far, the phase 2 data on CP101 was generally positive for the treatment of recurrent C difficile infections.

A new-user comparator study of adults with type 2 diabetes indicates use of SGLT2 inhibitors was associated with a 54% lower risk of hospitalizations for heart failure and a 15% lower risk of a modified MACE outcome compared to use of DPP-4 inhibitors.